PDS Biotechnology Corp (PDSB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $113.39M
Last updated: Nov 17, 2026 at 4:43 PM ET
PDS Biotechnology Corp (PDSB) Stock Chart
PDS Biotechnology (PDSB) has a latest price of $0.89 on Nov 17, 2026, 50.1% below its 52-week high of $1.79. Its price rose 6.3% over the past 12 months. The month-end price fell 99.3% over the 10 years through Oct 2026, a compound annual decline of 39.2%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $301.00 in Feb 2018 and its lowest $0.21 in Aug 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart PDSB with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for PDSB.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 345.3%, and over 6 months it fell 10.6%. The month-end price fell 65.5% over the 3 years through Oct 2026, a compound annual decline of 29.8%.
| Period | Change |
|---|---|
| 1 month | -2.5% |
| 3 months | +345.3% |
| 6 months | -10.6% |
| 12 months | +6.3% |
| 12 months, with dividends | +6.3% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -65.5% | -29.8% |
| 5 years | -88.0% | -34.6% |
| 10 years | -99.3% | -39.2% |
Price by Year
Its best calendar year was 2021, when the price rose 278.5%, and its weakest was 2018, when it fell 96.6%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $1.44 | +87.1% |
| 2025 | $0.77 | -52.8% |
| 2024 | $1.63 | -67.2% |
| 2023 | $4.97 | -62.3% |
| 2022 | $13.20 | +63.0% |
| 2021 | $8.10 | +278.5% |
| 2020 | $2.14 | -19.2% |
| 2019 | $2.65 | -58.7% |
| 2018 | $6.42 | -96.6% |
| 2017 | $187.40 | -25.0% |
Trading Range
The price is 11.7% below its 50-day average of $1.01 and 6.3% above its 200-day average of $0.84.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $0.89 | |
| 52-week high | $1.79 | -50.1% |
| 52-week low | $0.20 | +358.4% |
| 50-day average | $1.01 | -11.7% |
| 200-day average | $0.84 | +6.3% |
Price Risk
Over 3 years, its largest fall from a peak was 97.0%.
| Measure | Value |
|---|---|
| 1-year beta | 2.44 |
| Largest fall, 1 year | -86.0% |
| Largest fall, 3 years | -97.0% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About PDSB
What is PDSB's 1-year price change?
PDS Biotechnology's price rose 6.3% over the past 12 months. With dividends included, the 12-month total return was 6.3%.
What is PDSB's 5-year price change?
PDS Biotechnology's month-end price fell 88.0% over the 5 years through Oct 2026, a compound annual decline of 34.6%. These figures leave out dividends.
What is PDSB's 52-week high and low?
PDS Biotechnology's 52-week high is $1.79 and its 52-week low is $0.20. Its latest price of $0.89 on Nov 17, 2026 is 50.1% below the high.
What is PDSB's beta?
PDS Biotechnology's 1-year beta against the S&P 500 is 2.44, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 86.0%.
Is the PDSB chart free?
Yes. Advanced Charting for PDSB is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
PDSB pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors